Skip to content

Therapeutic responses to Subcutaneous versus Intra-sheath sonographically guided corticosteroid injection in the management of Trigger Finger

Therapeutic responses to Subcutaneous versus Intra-sheath sonographically guided corticosteroid injection in the management of Trigger Finger

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201202187274N3
Enrollment
166
Registered
2012-04-04
Start date
2012-03-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigger Finger. Trigger finger, Nodular tendinous disease

Interventions

Intervention 1: Intervention group: 1 c.c of "Methyl-prednisolon acetate" 40 milligrams plus 1 c.c of "lidocaine" 2% will be injected subcutaneously under sonographic guidance. Intervention 2: Control
Treatment - Other
Intervention group: 1 c.c of "Methyl-prednisolon acetate" 40 milligrams plus 1 c.c of "lidocaine" 2% will be injected subcutaneously under sonographic guidance.
Control group: 1 c.c of "Methyl-prednisolon acetate" 40 milligrams plus 1 c.c of "lidocaine" 2% will be injected intra-sheath under sonographic guidance.

Sponsors

Vice chancellor for research, Guilan University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: having three symptoms of pain and tenderness at the position of A1 pulley, feeling pain and discomfort when flexing and extending finger, and nodule palpation. Exclusion Criteria: Any kind of concomitant local Tenosynovitis such as DeQurvain Disease, carpal tunnel syndrome, and Dupuytren's Contracture; clinical doubt to other diseases with similar symptoms and their affirmation in executed investigations; any history of local injection of corticosteroid; and any associated medical conditions such as diabetes melitus, rheumatoid arthritis and hypothyroidism.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Therapeutic response (Decrease in Quinnell's grade). Timepoint: Before first injection, 3 and 6 weeks, 3 and 6 months and 1 year after first injection. Method of measurement: Quinnell's grade.

Secondary

MeasureTime frame
Reinjection. Timepoint: 3 and 6 weeks, 3 and 6 months and 1 year after first injection. Method of measurement: Number.;Open Surgery. Timepoint: 6 weeks, 3 and 6 months and 1 year after first injection. Method of measurement: Number.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Mardani Kivi MD.

Guilan University of Medical Science

mardani@gums.ac.ir+98 13 1321 1470

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026